| Literature DB >> 22272696 |
Tianxiang Chen1, Dongli Song, Zhihui Min, Xiangdong Wang, Yu Gu, Bajin Wei, Jia Yao, Kangjie Chen, Zhijun Jiang, Haiyang Xie, Lin Zhou, Shusen Zheng.
Abstract
BACKGROUND: Intratumoral and circulating regulatory T cells (Tregs) have been shown to be critical in the pathogenesis of hepatocellular carcinoma (HCC). However there is limited knowledge on the alterations of regulatory B cells (Bregs). We here investigated perioperative dynamic alterations of peripheral circulating Tregs and Bregs in HCC patients to reveal the relationship between regulatory lymphocytes and its clinical implications.Entities:
Mesh:
Year: 2012 PMID: 22272696 PMCID: PMC3292477 DOI: 10.1186/1479-5876-10-14
Source DB: PubMed Journal: J Transl Med ISSN: 1479-5876 Impact factor: 5.531
Figure 1Frequencies of peripheral regulatory T cells of different study groups. Frequencies of peripheral regulatory T cells were analysed in the healthy donor (Healthy), patients with chronic hepatitis B infection (CHB), and patients with hepatocellular carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about 7 days (HCCa7) after surgery. Representative flow cytometry analysis of peripheral CD4+CD25+CD127- populations were measured and presented (A). Frequency of CD4+CD25+CD127- cells of total CD4+ T cells in the peripheral blood were calculated (B). The mean ± SEM is shown,* and ** stand for P < 0.05 and 0.01, respectively.
Figure 2Frequencies of peripheral regulatory B cells of different study groups. Frequencies of peripheral regulatory B cells were analysed in the healthy donor (Healthy), patients with chronic hepatitis B infection (CHB), and patients with hepatocellular carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about 7 days (HCCa7) after surgery. Representative flow cytometry analysis of peripheral IL10+CD19+ cells were measured and presented (A). Frequency of IL10+CD19+ cells of total CD19+ B cells in the peripheral blood (B). The mean ± SEM is shown, *, **and *** stand for P < 0.05, 0.01 and 0.001 respectively.
Figure 3Perioperative kinetics of peripheral lymphocytes of patients with hepatocellular carcinoma. Frequency (A) and numbers (B) of lymphocytes in patients with hepatocellular carcinoma (HCC) before surgery (HCCb), 1-2 days (HCCa1) or about 7 days (HCCa7) after surgery. The mean ± SEM is shown, ** and *** stand for P < 0.01 and 0.001, respectively.
Difference of clinical features between HCC patients at low and high stages of TNM (AJCC).
| Variables | Mean Rank | ||
|---|---|---|---|
| Stage Low | Stage High | ||
| Platelet ×109/L | 16.77 | 23.00 | 0.034 |
| Thrombocytocrit % | 17.19 | 21.90 | 0.027 |
| Cystatin C mg/L | 16.08 | 24.80 | 0.003 |
| Albumin/Globin | 16.38 | 24.00 | 0.032 |
| High density lipoprotein mmol/L | 15.88 | 25.30 | 0.001 |
| α-fetoprotein ng/ml | 16.46 | 23.80 | 0.046 |
| Ferritin ng/ml | 15.62 | 26.00 | 0.004 |
| Numbers of up-regulated tumor markers | 15.48 | 26.35 | 0.003 |
| Multiple Satellite nodules | 16.77 | 23.00 | 0.053 |
| Tumor encapsulation | 16.88 | 22.70 | 0.022 |
| score of Pathology section | 15.58 | 26.10 | 0.007 |
| Score of Tumor markers | 16.35 | 24.10 | 0.042 |
| Total score | 16.27 | 24.30 | 0.040 |
Stage low: TNM (AJCC) stage I. Stage high: TNM (AJCC) stage II-IV.
HCC: Hepatocellular carcinoma; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on Cancer).
Correlations between total DESS scores and clinical stages of HCC patients.
| Total DESS scores | ||
|---|---|---|
| Staging system | ||
| TNM (AJCC) stage | 0.365 | 0.029 |
| TNM (lCSGJ) stage | 0.364 | 0.029 |
| CLIP score | 0.474 | 0.004 |
| BCLC stage | 0.501 | 0.002 |
| Child-Pugh grade | -0.121 | 0.482 |
DESS: Digital evaluation scoring system; HCC: Hepatocellular carcinoma; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on Cancer); TNM (LCSGJ): Tumor-Node-Metastasis Staging System (Liver Cancer Study Group of Japan); CLIP: Cancer of the Liver Italian Program Score; BCLC: Barcelona Clinic Liver Cancer Staging System.
Correlations of clinical features of HCC patients with circulating Tregs and Bregs.
| DESS evaluated | Tregs | Bregs | ||
|---|---|---|---|---|
| Clinicopathological Characteristic | ||||
| Weight Loss | -0.339 | 0.043* | - | - |
| HBV Infection History | 0.360 | 0.031* | - | - |
| Leucocyte | 0.363 | 0.029* | - | - |
| Hepatitis B e Antigen | - | - | 0.527 | 0.030* |
| HBV DNA Copy number | - | - | 0.532 | 0.028* |
| Ferritin | -0.451 | 0.006** | - | - |
| Numbers of up-regulated tumor markers # | -0.376 | 0.024* | - | - |
| Portal vein tumor thrombosis | -.408* | 0.014* | - | - |
| Hepatic vein invasion | -.413* | 0.012* | - | - |
| BCLC score | -0.443 | 0.007** | - | - |
| TNM stage(AJCC) | -0.347 | 0.038* | - | - |
(*, ** stands for P < 0.05, 0.01, respectively)
# Tested tumor markers:α-fetoprotein; cancer antigen 125; cancer antigen 153; cancer antigen 199; Ferritin; Carcino-embryonic antigen; prostate specific antigen.
HCC: Hepatocellular carcinoma; Tregs: Regulatory T cells; Bregs: Regulatory B cells; HBV: Hepatitis B virus; BCLC: Barcelona Clinic Liver Cancer Staging System; TNM (AJCC): Tumor-Node-Metastasis Staging System (American Joint Committee on Cancer).